Smith & Nephew SNATS Inc
$ 34.35
1.03%
14 Apr - close price
- Market Cap 14,510,720,000 USD
- Current Price $ 34.35
- High / Low $ 34.41 / 34.09
- Stock P/E 23.78
- Book Value 2.49
- EPS 1.43
- Next Earning Report 2026-05-06
- Dividend Per Share $0.39
- Dividend Yield 2.3 %
- Next Dividend Date 2026-05-27
- ROA 0.05 %
- ROE 0.12 %
- 52 Week High 37.90
- 52 Week Low 24.86
About
Smith & Nephew plc develops, manufactures, markets and sells medical devices worldwide. The company is headquartered in Watford, the United Kingdom.
Analyst Target Price
$36.62
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-24 | 2025-11-06 | 2025-08-05 | 2025-04-30 | 2025-02-25 | 2024-10-31 | 2024-08-01 | 2024-05-01 | 2024-02-27 | 2023-11-02 | 2023-08-03 | 2023-04-26 |
| Reported EPS | 0.38 | 0 | 0.33 | 0 | 0.23 | 0 | 0.756 | 0 | 1.31 | 0 | 0.35 | 0 |
| Estimated EPS | 1.12 | 0 | 1.03 | 0 | 0.97 | 0 | 0.93 | 0 | 0.96 | 0 | 0.81 | 0 |
| Surprise | -0.74 | 0 | -0.7 | 0 | -0.74 | 0 | -0.174 | 0 | 0.35 | 0 | -0.46 | 0 |
| Surprise Percentage | -66.0714% | None% | -67.9612% | None% | -76.2887% | None% | -18.7097% | None% | 36.4583% | None% | -56.7901% | None% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-06 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | 0 |
| Currency | USD |
Previous Dividend Records
| May 2026 | Nov 2025 | May 2025 | Nov 2024 | May 2024 | Nov 2023 | May 2023 | Oct 2022 | May 2022 | Jan 1970 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Payment Date | 2026-05-27 | 2025-11-07 | 2025-05-28 | 2024-11-08 | 2024-05-22 | 2023-11-01 | 2023-05-17 | 2022-10-26 | 2022-05-11 | None |
| Amount | $0.482 | $0.3 | $0.462 | $0.288 | $0.462 | $0.288 | $0.462 | $0.288 | $0.462 | $0.288 |
Next Dividend Records
| Dividend per share (year): | $0.39 |
| Dividend Yield | 2.3% |
| Next Dividend Date | 2026-05-27 |
| Ex-Dividend Date | 2026-03-27 |
Recent News: SNN
2026-04-14 19:10:15
Smith & Nephew plc, a global medical technology company listed in London, offers U.S. investors exposure to the resilient orthopaedics market, driven by aging populations and demand for joint replacements. The company diversifies its revenue across orthopaedics, sports medicine, and advanced wound management, maintaining a strong competitive edge through innovation and surgeon preference. Key risks include supply chain disruptions, regulatory hurdles, and currency volatility, but analysts generally view the company positively for its defensive growth and innovation pipeline.
2026-04-14 15:10:14
Smith & Nephew (SNN) has submitted an amended Form 6-K/A to clarify how investors can access its 2025 Annual Report, 2026 AGM materials, and proposed new Articles of Association. The company confirmed these documents are available on the UK National Storage Mechanism and its website, and that hard copies are available free of charge to shareholders and ADS holders upon request. This amendment primarily adds wording about the free availability of hard copies to enhance investor access.
2026-04-14 11:10:15
Smith & Nephew plc is well-positioned for growth in the global medtech sector, particularly in orthopedics and sports medicine, driven by an aging population and increasing demand for joint replacements. The company's diversified business model, focus on innovation, and strong market presence in the U.S. and other English-speaking markets make it an attractive option for investors seeking exposure to resilient healthcare spending. Key growth drivers include accelerated innovation in robotics and digital surgery, expanding market access, and operational discipline, despite facing risks such as supply chain disruptions and competitive pressures.
2026-04-10 20:09:26
Smith+Nephew announced new randomized control trial data showing that its REGENETEN Bioinductive Implant significantly reduces post-operative recovery times for patients with partial-thickness rotator cuff tears, with healing rates comparable to traditional surgery. Patients treated with the implant returned to daily activities twice as fast and reported a better quality of life. This is the third RCT demonstrating the implant's effectiveness, reinforcing its role in redefining rotator cuff repair.
2026-04-09 19:39:47
Smith+Nephew announced new randomized control trial data for its REGENETEN Bioinductive Implant, demonstrating that it halves post-operative recovery times for partial-thickness rotator cuff tears compared to traditional suture anchor repair. The study, published in the Orthopaedic Journal of Sports Medicine, also highlighted improved quality of life for patients and high tendon healing rates. This evidence supports the implant's increasing importance in rotator cuff injury treatment, aligning with updated guidelines from the American Academy of Orthopaedic Surgeons.
2026-04-09 12:10:01
Smith+Nephew announced new randomized control trial data showing that its REGENETEN Bioinductive Implant significantly reduces post-operative recovery times for patients with partial-thickness rotator cuff tears. Patients treated with REGENETEN experienced halved recovery times for daily activities and a better quality of life compared to traditional suture anchor repair, while maintaining similar high healing rates at one year. This study marks a significant improvement in the standard of care for these injuries, with over 250,000 procedures completed globally since 2014.
